Full-Time
Posted on 7/17/2025
Clinical-stage biopharma developing CNS therapies
$85k - $100k/yr
Remote in USA
Remote
| , , , , |
Praxis Precision Medicines develops therapies for central nervous system (CNS) disorders, with a focus on conditions caused by neuronal imbalance and genetic epilepsies. Its products aim to restore balance in CNS networks by applying genetic epilepsy insights, progressing through clinical development toward potential commercialization. What sets Praxis apart is its commitment to patient-guided development, incorporating patient and caregiver needs into therapy design, alongside strategic partnerships with other healthcare entities. The company's goal is to deliver effective CNS treatments to patients and caregivers and advance collaborations that support clinical development and eventual market access.
Company Size
201-500
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Stock Options
Company Equity
Performance Bonus
Unlimited Paid Time Off
Paid Holidays
Flexible Work Hours
Driehaus Capital Management has invested $80.5 million in Praxis Precision Medicines, purchasing 432,510 shares and bringing its stake to 1.87% of assets under management. The transaction, disclosed on 17 February 2026, increased Driehaus's position value by $248.5 million, reflecting both the purchase and share price appreciation. Praxis shares have surged 685% over the past year to $303.37, giving the company an $8.4 billion market capitalisation. The biotech firm recently submitted two FDA applications: ulixacaltamide for essential tremor and relutrigine for rare developmental epilepsies. CEO Marcio Souza estimates the company's four late-stage programmes could generate over $20 billion in revenue if commercialised. Praxis ended 2025 with $926 million in cash and raised an additional $621 million in January, providing funding through 2028.
- **New Investment Disclosure**: On February 13, 2026, Affinity Asset Advisors disclosed a new position by acquiring 185,000 shares of Praxis Precisio...
Affinity Asset Advisors has disclosed a new position in Praxis Precision Medicines, acquiring 185,000 shares valued at $54.53 million during the fourth quarter. The stake represents 3.11% of the fund's reportable assets. Praxis shares were trading at $317.25 as of 13 February 2026, up 266% over the past year. The Boston-based clinical-stage biotechnology company develops therapies for central nervous system disorders, with lead candidates targeting major depressive disorder, essential tremor and epilepsy. The company expects two new drug application submissions by mid-February and holds approximately $956 million in cash and investments, sufficient to fund operations into 2028. Third-quarter research and development expense reached $65.8 million, whilst net loss widened to $73.9 million.
Participation from top-tier healthcare investors recognizes momentum across breadth of its CNS therapeutics portfolio CAMBRIDGE, Mass.--Praxis Precision Medicines, Inc., a clinical-stage company translating genetic insights into the development of therapies for people with central nervous system
CAMBRIDGE, Mass. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced